CalciMedica (NASDAQ:CALC) Given Buy Rating at HC Wainwright

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $16.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 370.59% from the stock’s current price.

CalciMedica Stock Down 2.6 %

CALC stock opened at $3.40 on Thursday. The firm’s 50-day simple moving average is $4.12 and its 200 day simple moving average is $4.56. The stock has a market cap of $36.55 million, a PE ratio of -2.43 and a beta of 1.30. CalciMedica has a fifty-two week low of $2.68 and a fifty-two week high of $8.38.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.03. Equities analysts forecast that CalciMedica will post -2.21 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Sanderling Venture Partners Vi purchased 86,867 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was purchased at an average cost of $3.75 per share, with a total value of $325,751.25. Following the purchase, the insider now owns 814,300 shares in the company, valued at $3,053,625. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other CalciMedica news, major shareholder Sanderling Venture Partners Vi purchased 86,867 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were purchased at an average price of $3.75 per share, for a total transaction of $325,751.25. Following the completion of the transaction, the insider now owns 814,300 shares in the company, valued at $3,053,625. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Fred A. Middleton acquired 87,744 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were bought at an average price of $3.75 per share, with a total value of $329,040.00. Following the transaction, the director now directly owns 814,300 shares in the company, valued at approximately $3,053,625. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 312,944 shares of company stock worth $1,172,910. 41.55% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CalciMedica stock. Atria Investments Inc increased its position in CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the period. Atria Investments Inc owned about 0.25% of CalciMedica worth $117,000 at the end of the most recent reporting period.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.